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Thanks to a never-before detailed view of the human genome, the last decade has brought to light the notion of DNA copy num-
ber variation (CNV) as the pivotal force contributing to population genomic diversity and evolution. It is as well clear now that 
cancer typically results in loosened control over genomic integrity and that the acquisition of somatic copy number alterations 
(SCNAs), whether confined to specific genes or affecting entire chromosome arms, is likely to be a fundamental prerequisite to 
the adaptive pressure that drives oncogenesis. This review gives a brief overview of key developments in genome-wide SCNA 
profiling, with specific emphasis on array-based techniques and deep-sequencing, which indeed enabled us to identify the large 
majority of genomic regions undergoing frequent alteration in human cancers and defining recognizable clinical phenotype. 
Alongside with the prospective to take advantage for future personalized precision medicine, high-throughput SCNA analysis 
have already proven diagnostic and prognostic potential, particularly for those clinically unpredictable and therapy-refractory 
tumors, such us cutaneous melanoma. Biomed Rev 2013; 24: 11-24
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introduction
Germline copy number variation (CNV) of genes and sin-
gle nucleotide polymorphism (SNP) are two major driving 
forces of biological evolution, contributing substantially to 
the genomic diversity between phenotypically normal indi-
viduals and conferring susceptibility to a variety of human 
diseases including cancer. However, CNVs are estimated to 
happen more frequently (10-5) compared to single-nucleotide 
substitutions (10-6) or single nucleotide insertion/deletion 
(10-7 - 10-8), giving potentially the strongest contribution for 
selective pressure (1). CNVs include deletions, duplications, 
insertions, and amplification that are in the range between 1 
kb and entire chromosome arms (1-4). These type of structural 
variations collectively constitute the so-called copy number 
polymorphism (CNP), which generally account for less than 
1% of the genomic variability in the human population (5-7). 
Possibly thousands of variable loci exist, comprising as much 
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as 12% (about 360 Mb) of the entire genome (2), with a con-
siderable fraction (>20%) involving protein coding genes with 
known or putative functional relevance (1,2). 
Excessive changes in DNA copy number may have ad-
verse influence on fitness and are, for the most part, highly 
detrimental, which keeps the population frequency of ger-
mline CNVs lower than 1% (6,7). Consequently, predispo-
sition to diseases is possibly driven by cumulative effect of 
single CNVs of multiple genes, which individually would 
have little or no influence. However, under strong selective 
pressure, such as that acting during neoplastic transforma-
tion, most of the genomic rearrangements involve individ-
ual genes or set of specific genes with strong phenotypic 
impact (8). 
Amplification of oncogenes and deletion of tumor-sup-
pressor genes are indeed the major drivers of tumorigenesis 
and the massive acquisition of somatic copy number chang-
es, called somatic copy number alterations (SCNAs), is a 
characteristic of all tumors (8,9). During the last decades, 
several methodologies have been developed to improve the 
resolution of genomic alteration analysis, bringing to light 
that there is a great variability in the number of SCNAs 
in human tumors (see the Mitelman Database of Chromo-
some Aberrations in Cancer, http://cgap.nci.nih.gov/Chro-
mosome/Mitelman), depending on the tumor type and the 
degree of aggressiveness, although structural mutations 
that give the strongest survival benefit are highly common 
across cancer.
This review will make a point of how the introduction of 
ever-more detailed genomic profiling platforms based on ar-
ray comparative hybridization (aCGH) and next-generation 
sequencing (NGS) have changed the understanding of the 
complex landscape of genome instability in cancer with im-
portant consequences for the diagnostic analysis and the pre-
diction of oncogenic progression. Specific attention will be 
given to cutaneous malignant melanoma (MM), for which 
conventional methods and traditional cytogenetic analysis do 
not always allow accurate preventive diagnosis of a tumor 
that, if taken at the earliest stages, will have elevated chances 
of favorable prognosis.
bioloGical implications of scnas 
Hotspot changes in single or small set of genes as well as 
large-scale SCNAs, including several megabases’ segmental 
alterations and whole-chromosome aneuploidies, constitute 
to the greatest part of genomic instability observed in cancer 
(9), and can have dramatic effect on the perturbation of many 
cellular pathways (10). Acquisition of SCNAs is potentially 
the most important contributor to the increased fitness of 
cancer cells under imposed selection and can promote rapid 
and specific resistance to therapeutic agents. Currently, non-
allelic homologous recombination (NAHR), which involves 
crossing-over between highly homologous DNA segments 
or tandem sequences of variable numbers of tandem repeats 
(VNTRs), during cell division, and non-homologous end 
joining (NHEJ), which is a highly conserved double strand 
DNA repair mechanism, are the best-studied routes through 
which SCNAs can be generated (9,11). Deregulation of these 
processes is typically facilitated in a context of polyploidy 
and consequent aneuploidy, which may represent the initial 
steps of genetic adaptation promoting oncogenesis (12). Dur-
ing continuous selective pressure, chromosomal aneuploidy 
is replaced by more subtle genetic changes, mainly SCNAs 
that achieve the same goal with less adverse effect than 
whole-chromosome gain/loss (13,14). Mutations that may 
suppress the detrimental consequences of genomic instability 
may also enhance the survival advantage conferred by SC-
NAs. Indeed loss of p53 is a major contributor to tumorigen-
esis (15) by inducing toleration to the DNA-damage response 
that follows genomic rearrangements and chromosome mis-
segregation (16,17).
As a consequence, most advanced tumors usually present 
much complex patterns of molecular rearrangements in their 
genome, generally due to breakage of chromosomes during 
cytokinesis and inefficient replication (18). In some cases 
these defects culminate in the extreme phenomenon of chro-
mothripsis, a recently discovered and rare catastrophic event 
that can randomly affect one or a few chromosomes in about 
2-3% of tumors (19,20). This feature is associated to most 
aggressive prognosis in patients and is potentially due to the 
formation of extra-genome micronuclei (double minutes) 
after chromosome segregation defects that undergo further 
fragmentation and rearrangements (21).
Altogether these karyotype changes contribute to the dra-
matic scenario observed in cancer. Whether eliciting cumula-
tive phenotypes that are independent of the identity of the 
genes involved or inducing direct effects on the expression 
level of specific genes, duplications, amplifications, dele-
tions, and whole-chromosome gains or losses are the hall-
mark of cancer and are apparently much more pivotal and 
frequent compared to single-nucleotide alterations, than pre-
viously thought.
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from traditional methods to hiGh-throuGhput  
whole-Genome mappinG of scnas
Conventional cytogenetic banding techniques usually allow 
the detection of segmental alterations not smaller than 5-10 
Mb (22), which limits the analysis only to gross, well-recog-
nizable chromosomal rearrangements. With the introduction 
in the 1990s of molecular approaches, such as fluorescence 
in situ hybridization (FISH), into the clinical testing and ge-
netic research it was possible to discover a number of novel 
genomic micro alterations by the ability of hybridizing spe-
cific fluorescent DNA-probes on metaphase chromosomes or 
interphase nuclei (23). However, the sensitivity of FISH is 
limited by both the size of the probe and by the fact that only 
regions recognized by specific probes can be queried. Simi-
larly to FISH, the use of traditional genomic comparative hy-
bridization (CGH) employs metaphase chromosome as the 
hybridization target and is unable to reveal submicroscopic 
alterations that involve less than 5 Mb or that are closely 
spaced (24), although it has been proven as a robust and far-
used method for the identification of cancer-associated copy 
number imbalances (25,26). SCNAs are assessed by hybrid-
izing differentially labeled DNA from a tumor sample and 
reference genome (from normal individuals or match-paired 
patient’s healthy tissue) to metaphase spreads. The ratio of 
tumor/reference competitive hybridization signals is used to 
determine the relative amount of tumor sequences with re-
spect to normal counterpart along the chromosome segments.
The limit in resolution of these early techniques has been 
finally overcame only with the completion of the Human Ge-
nome Project (27) and the advent of DNA microarray-based 
technologies, such as aCGH and SNP-based arrays (28-31), 
leading to the explosion of information revealing the preva-
lence of SCNAs in cancer (32,33). Array CGH is based on 
the similar principle of traditional CGH, with the difference 
that a microarray chip of genomic probes has replaced the 
metaphase chromosome spreads as hybridization platform 
(28). In SNP array technology there is no comparative com-
petition and sequence-specific oligonucleotides, homologous 
to the different SNP alleles existing in the human genome, 
are arrayed on a chip where fragmented test DNA is hybrid-
ized; depending on their SNP genotype, fragments bind only 
to the specifically-matched probe and give rise to a fluores-
cent signal detected by a scanner (30,31). 
With a single-run experiment these array-based approach-
es can detect whole-genome SCNAs that would require hun-
dreds of traditional tests, providing on top of that an empow-
ered resolution. The main limitation, however, of array-based 
techniques is the ability to detect aberration involving copy 
number changes only: balanced translocations and inver-
sions are not detectable with this methodology. Furthermore, 
results of array experiments have to be generally validated, 
through FISH (23) or genomic real-time quantitative PCR, 
to confirm copy number changes of a specific test locus (34).
The sensitivity to detect genomic rearrangements has fur-
ther escalated with the advent of NGS, or whole-genome se-
quencing (WGS), technology (35,36). This revolutionizing 
approach is potentially capable of providing information at 
single-nucleotide resolution of full cancer genomic mutation 
repertoire, including SCNAs, inversions, translocations, in-
sertions, point mutations, breakpoints of SCNAs, and epige-
netic changes in the DNA (35). 
Finally, to correctly interpret the copy number data relat-
ed to cancer genome, we must distinguish abnormal lesions 
from normal genomic variants present in the human popula-
tion. Information about normal genomic variations are now 
publically available (Database of genomic variants, http://
dgv.tcag.ca/dgv/app/home; Database of Single Nucleotide 
Polymorphisms, http://www.ncbi.nlm.nih.gov/SNP/) and, 
in principle, may be integrated with data of cancer genomic 
profiles, deposited in similar accessible database (UCSC Ge-
nome Browser, http://genome.ucsc.edu/; Gene Expression 
Omnibus, http://www.ncbi.nlm.nih.gov/geo/; ArrayExpress, 
http://www.ebi.ac.uk/arrayexpress/; Integrative Genomics 
Viewer, http://www.broadinstitute.org/igv/) to crate a cohe-
sive framework that will facilitate the understanding of can-
cer genomic complexity. Especially, The Cancer Genome At-
las (TCGA) demonstrates the power of integrative analyses 
coming from multiple experiments on a large series of cancer 
tissues (http://cancergenome.nih.gov/).
array comparative Genomic hybridization in cancer 
During the past several years however, before the advent of 
NGS, aCGH has been extensively used as the gold-standard 
approach to assess genomic copy number changes in basi-
cally all human diseases (24,37,38). Especially, aCGH data 
have contributed enormously to the high-resolution mapping 
of specific genomic alterations and subsequent identification 
of target genes associated to cancer classification, disease 
progression, therapy response, and patient outcome in vari-
ous tumor types (8,26,33). Particularly, oligo-based aCGH 
provided a wealth of information in cancer at genome-wide 
level with a cost-effective benefit compared to NGS and with 
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much higher resolution than previous methods (39,40).
The detection limit of aCGH depends on the probe density 
(the distance between each target distributed along the entire 
genome) and the size of the probes (41). This will establish 
the resolution of the chip used. The DNA probes range from 
genomic clones, most often bacterial artificial chromosome 
(BAC) clones (20-200 Kb), to oligonucleotides probes (20-
80 bp). For example, if clones are spaced by 1 Mb intervals, 
everything that is smaller than 1 Mb will not be detected. 
With the introduction of oligonucleotide arrays the sensitivity 
has greatly enhanced: in a chip containing 1 million probes, 
potentially the sensitivity could be less than 500 bases, which 
is very close to highest-resolution SNP arrays (40,42).
In oligonucleotide aCGH analysis of cancer, total genom-
ic DNA isolated from a tumor and normal control sample 
are labeled with two different fluorochromes (Cy5 and Cy3 
respectively) and hybridized on a chip where the oligonu-
cleotide probes corresponding to the human genome are ran-
domly spotted (Fig. 1). The resulting ratio of the fluorescence 
intensity (usually expressed as log2 ratio) between the two 
fluorochromes at each DNA sequence is approximately pro-
portional to the ratio of copy numbers of the corresponding 
genomic locus. Hybridization results are further analyzed by 
specific algorithms to distinguish differences between DNA 
copy numbers and the values are normalized so that the me-
dian log2 ratio is set to zero. Values of log2 around +1 indi-
cate gain of one extra copy number (duplication) and above 
+2 indicate gain by a factor of four in copy number (ampli-
fication). Ratio near -1 indicates hemizygous deletion, while 
ratio below -2 (theoretically log2 of - ∞) indicates homozy-
gous deletion (Fig. 1). Additional validation of the result is 
typically made by genomic quantitative PCR.
Although oligonucleotide aCGH arrays cannot identify 
breakpoints at the single-nucleotide level, recent high-reso-
lution oligonucleotide platforms have narrow down consid-
erably the accuracy of SCNA genotyping (39). An additional 
limit of aCGH technology is the impossibility to identify 
other types of genomic rearrangements than copy number 
changes, such as translocation and loss of heterozygosis 
(LOH). Nevertheless, for a number of different reasons, in-
cluding friendly costs and manageable data analysis, aCGH 
remains the most convenient high-throughput method for 
precise genome-wide detection of SCNAs with direct diag-
nostic and clinical application (43).
Thanks to this technology, a number of regions that are 
frequently altered in cancer have been identified, giving a 
comprehensive picture of the most recurrent patterns of SC-
NAs (8). For example, there are common regions of gain/loss 
harboring well-established cancer-related genes that are the 
hallmark of many tumors. These may include gain and am-
plification of oncogenes such as HRAS, CCND1 or deletion 
of tumor suppressors like CDNK2A, PTEN that can indeed be 
commonly observed across different tumor types (8,39). At 
the same time, characterization of tumor-specific genes, such 
as NMYC amplification in neuroblastoma (44,45), ERBB2 
amplification in mammary tumors (46,47), or MITF, the es-
sential transcription factor involve in melanin production 
and melanocyte differentiation, in melanoma (48), have been 
exploited to draw a complete tumor classification based on 
SCNA profiles (49-52). 
next Generation sequencinG of tumor Genomes
The advent of NGS has brought a real revolution to the study 
of human genome biology (35). What initially had required 
over 13 years to sequence the entire human DNA now has in-
credibly reduced to potentially less than fifteen days (53,54). 
Most importantly, the rising of this technology has opened a 
new era of cancer genetics, starting in 2008 with the first can-
cer genome completely sequenced of a case of acute myeloid 
leukemia (55-57). Compared to previous method and array-
based technology, NGS can provide a comprehensive picture 
of the cancer genome (58-60). In principle, single-nucleotide 
substitutions, small insertion or deletions, as well as chromo-
some rearrangements, including effects due to transposon el-
ements, SCNAs, translocations, and chromosome insertions, 
can all be detected in a single run of reading (35,56). In addi-
tion, NGS is able to reveal mutations in non-coding regions, 
including promoters, enhancers, introns, non-coding RNAs, 
microRNAs (35,58), and epigenomic changes (61).
The experimental approach of NGS is based not on a 
unique technique but consists of a broad number of differ-
ent methods required for the template preparation, imaging 
of the signals and data analysis (59,62). The combination of 
specific protocols distinguishes the type of data retrievable 
from the different platforms available (62,63). Major dif-
ferences are in the template preparation however; although 
a common theme is that the template DNA is amplified to 
form a library, which is then immobilized so to allowed thou-
sands of sequencing reaction to happen simultaneously (63). 
Individual DNA fragments of the library, originated from a 
single molecule of genomic DNA, are amplified either on 
beads or on flat surface prior to sequencing reaction and each 
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Oligonucleotide array chip





















Hybridization on the array
Cy5/Cy3 hybridization signal for distinct probe sets
Figure 1. Schematic representation of the procedure used to assess SCNAs in tumors by oligonucleotide aCGH. A. Array CGH 
involves competitive hybridization of tumor test DNA and reference diploid DNA samples (differentially labeled with red Cy5 
and green Cy3) to a pre-designed set of probes covering the entire genome, which are spotted on a chip microarray slice. B. For 
each gene or genomic sequence included in the array, the hybridization signal is a result of the average intensity from multiple 
probes representing the same gene, spotted in a specific well on the array. The image shows an aCGH experiment of a MM pa-
tient (labeled red) compared with normal tissue (labeled green). Red color indicates increased DNA copy number, green repre-
sents loss of genomic sequence (that is a deletion), while yellow represents no changes (diploidy). Inset, red/green hybridization 
signals are represented for selected spots. Unpublished data, courtesy of A. Quattrone (Laboratory of Translational Genomics, 
CIBIO, University of Trento, Italy). C. The Cy5/Cy3 ratios of signal intensity are then measured for each probe (generally as 
log2 ratio) and normalized so that significant deviations from zero indicate variation (loss or gain) in the copy number of that 
particular DNA fragment in the test sample, relative to the reference, as exemplified here. 
MM, malignant melanoma; SCNA, somatic copy number alteration; aCGH, array comparative hybridization.
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sequence read is equivalent to a single DNA fragment (63). 
For a detailed explanation of these technical procedures and 
descriptions of commercially available platforms, I would re-
fer the reader to specific reviews (35,56,62,63). 
Over the past two years, NGS technique has given a great 
boost to the field of cancer genome. In the investigation of 
SCNAs, NGS offer substantial benefits over aCGH, includ-
ing higher resolution (up to the level of single-nucleotide 
insertion/deletion while the minimum current resolution of 
array methods is the order of 0.1-0.5 kb) and precise locali-
zation of the breakpoints that cause SCNAs (59,63). Moreo-
ver, unlike aCGH, measurements taken by NGS do not suf-
fer of intensity saturation problems and therefore permit a 
more accurate estimation of the signals (62). Another im-
portant advantage of NGS lays in the possibility to detect 
rearrangements in highly repetitive sequences (Alu, LINE, 
centromeres) that were previously totally missed by aCGH 
analysis (56). Finally, before the NGS technology, there was 
no high-throughput method to define precise sites of chro-
mosomal rearrangements, like inversions and translocations, 
which were roughly identified by cytogenetics only in spe-
cific subset of tumors where those are particularly frequents, 
such as chronic myeloid leukemia and sarcoma (64). 
One major potential of genome sequencing for modern 
cancer research is possibly the rapid discovery of novel and 
chromosomal rearrangements. However, major applications 
of NGS are oriented to targeted sequencing of a region of in-
terest, like exon sequencing, which can be executed at lower 
costs and higher throughput way compared to a whole-ge-
nome shotgun sequencing. In cancer, transcriptome sequenc-
ing (RNA-seq) is a selective and efficient approach to detect 
intragenic fusions, point mutations, and changes in gene ex-
pression in a single-run experiment, especially for transcripts 
with low-level expression (60,64-66). Additionally, NGS has 
moved further ahead from just DNA sequence analysis to-
ward a number of different applications that have consider-
ably improved our understanding of nucleic-acid biology and 
gene expression mechanisms (67).
Altogether, with the aim to define new approaches for the 
discovery of variants associated with specific response to 
therapy (68) and predisposition to disease (69), NGS technol-
ogy has found an important application in the genome-wide 
association studies (GWAS) (35). Comparing allele frequen-
cy across the genomes of a large number of cases, thousand 
of genomic variants linked to the clinical heterogeneity in 
cancer can be found (58,70), opening the road to individual-
ized tumor treatment (69,71).
Overall, DNA cancer sequencing data have been collected 
in public-assessable repositories, among all TCGA database 
(72). Also, a complete catalogue of cancer-associated altera-
tions can be found at the COSMIC database, which stores a 
vast amount of information directly related to the publica-
tion links (www.cancer.sanger.ac.uk/cancergenome/projects/
cosmic).
copy number alteration analysis in maliGnant 
melanoma
The following paragraph of this review is focus to the ad-
vances obtained in the study of SCNAs in cutaneous ma-
lignant melanoma (MM). The majority of studies have 
been based on conventional CGH and aCGH (73,74), but 
recent introduction of NGS and the integration with previ-
ous mRNA expression and point-mutation data (75,76), may 
expand incredibly the information, concretizing the possibil-
ity to define predictive tools of patient outcome and therapy 
resistance (77,78).
Cutaneous MM is the most common cause of death (about 
65% of deaths) related to skin cancers and, despite account-
ing for some 4% of skin cancers and average 2% of all tu-
mors, its incidence is dramatically increasing (Fig. 2A); more 
than 60 000 new cases a year are diagnosed in Europe with 
over 10 000 estimated death (Fig. 2B), and the rate in North 
America and Australia is even higher (79,80). Primary tumor 
biopsy followed by histological inspection have long been 
considered the gold standard for diagnostic guidance (81,82) 
of MM, and thickness (Breslow thickness), denoted as the 
depth of tumor invasion, is a major independent indicator of 
neoplastic progression (83). In addition, since sentinel lymph 
nodes (SLNs) are the most likely primary site of metastasiza-
tion, sentinel-node biopsy is routinely used as the minimal 
essential procedure to evaluate the clinical prognosis (84). 
When detected at its early stages, cutaneous MM is almost 
90% curable (83). However, due to the total lack of symp-
toms during the initial phase of invasion and the difficulty to 
discriminate ambiguous lesions using conventional histolog-
ically criteria, cutaneous MM is often recognized after me-
tastasization to distant organs, when the prognosis is defini-
tively poor (83) and treatments are usually restricted to lym-
phadenectomy and postoperative non-curative chemotherapy 
(85,86). In this context, the introduction of molecular tests 
for SCNAs analysis has brought the diagnosis of the disease 
a step higher (73,77) and, with the advantage of genomic pro-
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> 60,000 new cases in Europe a year
Figure 2. Incidence and mortality of cutaneous MM. A. Incidence of cutaneous MM over other skin cancers. Basal cell car-
cinoma is by far the most frequent form of cancer in the human population worldwide and accounts for the 75% of tumors 
developing on the skin. However, basal cell carcinoma rate of date (0.8%) is more than ten-folder lower than the mortality rate 
associated to MM, where some 12% of patients affected by the disease die. MM represents only the 4% of all skin cancer but 
causes 65% of skin cancer-related death (80). B. Cutaneous MM incidence as percentage of total cancer cases in westernized 
countries. Recurrence of cutaneous MM is directly linked to sun exposure and light-skin phenotype, which explains its elevated 
frequency in Australia and New Zealand, where MM represents the second most common tyoe of cancer. In Europe, 60,000 total 
new cases are diagnosed every year (79,80).
MM, malignant melanoma.
filing, it has become clear the existence of genomic instabil-
ity patterns of highly recurrent SCNAs typically associated 
to this cancer (87). 
Malignant melanoma is a tumor that already at its primary 
condition shows profound patterns of SCNAs as revealed 
by aCGH (Fig. 3) and the association of specific SNCAs to 
known histopathological parameters and tumor progression 
phenotypes has long been pursued to the scope of defining 
early-development molecular biomarkers (52). Among all, 
CDKN2A is the first gene discovered that associates to fa-
milial susceptibility of developing MM (88,89) and the most 
common somatically deleted gene in MM (87,90,91). The 
importance of p16-RB pathway in MM is reinforced by the 
elevated frequency of CDK4 amplification (90,91). Other 
frequent SCNAs in MM are losses of regions in 6q23, 8p, 
and 10q and gains involving 1q, 4q12, 5p15, 6p25, 7q, 8q, 
11q13, 12q14, 17q, 19p, 20q and 22q (87,90-93). For most 
of these regions, the driver genes have not been identified, 
though other recurrent melanoma SCNA-driving genes 
have been characterized (87), including CDKN2A (deletion 
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Figure 3. An example of genomic aCGH profile of a primary MM associated with worst prognosis obtained by using Agilent oli-
gonucleotide array (Agilent Technologies, Santa Clara, CA). Most of the chromosomes reveal profound pattern of SNCAs. For 
each chromosome, the intensity of raw hybridization signals, between tumor DNA and diploid sex-matched control, is reported 
as log2 ratio (ordinate) plotted against chromosome map position (abscissa). Chromosome Y is not included in the analysis. 
Dashed lines indicate the upper and lover thresholds of diploid copy number. Gross genomic gains and losses are evident over 
the threshold bars (pointed by the arrows). Clear deletion of the entire 9p arm is present, including homozygous deletion (log2 
ratio < -2) of 9p21 where CDKN2A is located. DNA duplication is detected at the locus of CCND1 (11q13). Unpublished data, 
courtesy of A. Quattrone (Laboratory of Translational Genomics, CIBIO, University of Trento, Italy).
MM, malignant melanoma; SCNA, somatic copy number alteration; aCGH, array comparative hybridization.
of 9p21), PTEN (deletion of 10q23), KIT (amplification of 
4q12), CCDN1 (amplification of 11q13), and CDK4 (amplifi-
cation of 12q14). Often, type and number of SCNAs correlate 
with the specific histological subtypes (90,92,94). Further-
more, in this specific type of tumor, SCNAs analysis allowed 
a detailed sub-classification according to skin location of the 
primary site and exposure to UV, thus improving the disease 
diagnosis and bringing to the identification of subsets of pa-
tients with different clinical coursers (73,90). Comparison of 
tumor samples at different stages, such us premalignant or in 
situ lesion, invasive cancer, and metastatic disease, has also 
demonstrated that the overall number of SCNAs increases 
during tumor progression (76,95). Figure 4 shows some ex-
amples of SCNAs that are commonly associated to primary 
MMs as revealed by oligonucleotide aCGH.
Among all alteration associated to MM, constitutive ac-
tivation thought RAS/MAPK signaling is the leading cause 
of tumor progression, although the main genes involved in 
this pathway are preferentially mutated than amplified or 
gnomically altered (96). Specifically, MM displays the high-
est rate of constitutive kinase-activating mutations in BRAF 
gene over all human tumors (97,98) and NRAS is mutated 
in almost 15% of cases (98). At the same time, activation of 
PI3K/AKT cascade occurs in almost 30-40% of cases (96). 
The main event that causes deregulation of PI3K pathway is 
the deletion of PTEN (99), which is usually the second most 
recurrent homozygously deleted gene after CDKN2A in MM 
(90,100). Possibly, loss of PTEN is considered an essential 
step in the oncogenic progression of BRAF-mutated melano-
cytes (101). This has made, AKT and MAPK pathways, and 
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Figure 4. Visualization of genomic aCGH result for single chromosomes of primary MM samples. Data were obtained by using 
Agilent oligonucleotide array and filtered with Agilent Genomic Workbench software (Agilent Technologies, Santa Clara, CA). 
Intensity of the hybridization signals is reported as log2 ratio between tumor DNA and sex-matched diploid control (abscissa) 
and plotted against the chromosome map position (ordinate). Dashed lines indicate the upper and lover thresholds of gain/loss 
copy number. Color-filled areas denote a gain (right) of a loss (left). A. A patient showing amplification of region 11q13, where 
CCND1 gene is located, and concomitant deletion of adjacent segments. B. A patient showing focal amplification of MITF 
gene on chromosome 3. C. A patient with complete deletion of chromosome 9 and chromosome arm 10q, potentially driven by 
loss of CDKN2A and PTEN gene respectively, and a distinct breakpoint on chromosome arm 6q (arrow) that has generated an 
amplification followed by loss of nearby material. Unpublished data, courtesy of A. Quattrone (Laboratory of Translational 
Genomics, CIBIO, University of Trento, Italy).
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BRAF in particular, the most pursued clinical targets for the 
development of new drugs (102). A good fraction of patients 
with BRAF mutation seems to respond positively to specific 
targeted inhibition (103). However, it has been recently dis-
covered that tumor growth can be enhanced in the presence 
of RAS mutation by using BRAF inhibitors when BRAF is 
actually not mutated (104). Acquired resistance to BRAF-
targeted therapy may also depend on specific SCNA back-
ground and selective amplification of mutated-BRAF itself 
(105). Interestingly, mutation of CDK4 gene confers resist-
ance to BRAF inhibitors and this apparently only happens 
in concomitance with amplification of CCND1 (106). These 
finding further highlight the importance of accurate SCNA 
genome typing of individual patients in the clinical practice 
before making decision of therapeutic strategy.
Recent NGS whole-genome sequencing analyses have re-
inforced the accuracy of genomic alteration profiling of MM 
confirming most of the know SCNAs and posing the basis for 
the identification of novel MM-related genes (60,76,107,108). 
These studies have already provided a weight of information 
for the identification of a number of driving genes directly 
attributable to UV exposure for some of the most common 
SCNAs (60,76,107). Comparison of primary tumor and re-
lated metastasis has then proved the elevated signal accuracy 
of NGS with respect to array analysis of the same samples 
and revealed novel specific SCNAs that are acquired only by 
the metastatic tumor (108). 
Finally, a global approach of integrative analysis of mela-
noma genome sequencing and associated RNA-sequencing 
data has brought to the discovery of novel potential targetable 
molecules for therapeutic strategies (109). The integration of 
transcriptome sequencing data with accurate SCNAs profil-
ing and the association to the presence of important driving 
mutations, such as those in CDK4, BRAF or RAS genes, is at 
the moment only at the research level (76) but in the future 
might represent the scaffold for the development of appropri-
ate therapies.
conclusion
Structural polymorphism of DNA may have played a fun-
damental role in human evolution, by determining genetic 
diversity within the population, and have a significant part 
in disease development and predisposition. Germline CNVs 
across healthy individuals are widely distributed throughout 
the genome. However, some hotspot events are recurrent in 
regions of known somatic rearrangements under strong adap-
tive selection, like during tumorigenic progression. Profiling 
of driving cancer genetic alterations at increasingly higher 
resolution has been pursued intensively over the last decade 
bringing to the notion that SCNAs are a hallmark of cancer. 
Comprehensive high-resolution view of SNCAs in various 
tumor types, acquired with the introduction of NGS, has of-
fered a better understanding of cancer development and pro-
vides improved tools for the definition of novel diagnostic 
signature and therapeutic targets.
Identification of specific SCNAs for each patient that can 
be predictive of prognosis and guide pre-evaluation of thera-
peutic response is the goal in the clinical management of can-
cer. Particularly in those tumors, like cutaneous MM, that can 
be easily detected by dermatological inspection and rapidly 
removed from the primary site on the skin. High-throughput 
characterization of whole-genome SCNA profile of individ-
ual primary melanomas may become a real possibility in the 
next future and can provide immediate prognostic informa-
tion to decide the appropriate therapeutic options to be se-
lected for clinical trials. 
It is much probable that the ongoing innovation of genome 
sequencing will likely continue to advance and will continue 
to transform our view of cancer alteration landscape. Also, 
the increased availability of public data through The Cancer 
Genome Atlas will make available for the analysis by inde-
pendent groups an incredibly huge cohort of clinical sam-
ples. Translational genomics based on the integration of such 
a great amount of shared information will open the route to 
precision medicine of a disease that is extremely heterogene-
ous at the individual level. I would envisage a personalized 
sequencing approach for cancer diagnosis, based on the com-
parison of inherited and somatically acquired genetic chang-
es, to establish the best-tailored treatment for each patient. 
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